The utility of screening asymptomatic diabetic patients for coronary artery disease (CAD) has not been defined. The objective of the current study was to evaluate the impact of a strategy employing screening stress myocardial perfusion imaging (MPI) on short-term prognosis in diabetic patients without symptoms or known CAD, who otherwise had no indication for stress MPI. Methods: Asymptomatic diabetic males were enrolled in a strategy of screening stress MPI. All patients underwent routine MPI after exercise or dipyridamole stress using standard protocols, and were followed clinically for cardiac events (cardiac death, myocardial infarction, coronary angiography and revascularization). The Framingham global risk assessment score was used to for comparison of risk factors and to estimate the pre-test likelihood of CAD among patients. Results: In 44 asymptomatic diabetic males (age 66±8 years) without known CAD, 20 (45%) had an abnormal stress MPI (9 mildly abnormal, 11 moderately/severely abnormal). During short-term follow-up (18+3 months), there were no major adverse cardiac events in 33 patients with a normal or mildly abnormal stress MPI. Of 11 patients with a moderately/ severely abnormal MPI, 7 were subsequently referred for coronary angiography. All 7 had significant CAD (6 with left main coronary artery and/or 3-vessel CAD), and 5 of these patients required revascularization (4 surgical). The Framingham global risk profile score for CAD in patients with a normal/ mildly abnormal MPI was similar to those with a moderate/severely abnormal stress MPI (9.7±2.6 vs. 9.8±2.2, respectively, p=NS). Conclusion: A strategy of screening asymptomatic diabetics for CAD with stress MPI may be justified for additional risk stratification beyond clinical assessment. Patients with a normal or mildly abnormal stress MPI have a favorable prognosis, while those with a moderately/severely abnormal study (25% in this population) have a high incidence of severe CAD that may warrant assessment with angiography.
In Group 2, MBF at rest was 0.69±0.19 ml/g/min at baseline and 0.65±0.22 ml/g/min during the follow up (p=NS). Adenosine hyperemic MBF was at baseline 1.38±0.11 ml/g/min and 1.64±0.37 ml/g/min at follow-up (p=NS). During CPT, the rate pressor product (RPP) increased by 38±12% at baseline and 36±11% at follow-up (p=NS), and MBF by only 15±22% and 22±10% at baseline and follow-up, respectively (p=NS).
In the Group 1 patients, MBF at rest was 0.78±0.24 ml/g/min at baseline and 0.67±0.12 ml/g/min at follow-up (p=NS) and these were similar to Group 2. Hyperemic MBF was 1.85±0.30 ml/g/min at baseline and did no increase significantly at follow-up, 2.05±0.51 ml/g/min (p=NS). Importantly, for RPP increases of 21±13 and 28±16% (p=NS) by CPT, the MBF significantly increased from 10±11% at baseline to 33±18% at follow-up (p<0.01). Moreover, the percent of improvement in the MBF response to CPT from baseline to follow-up was significantly correlated with the percent decrease in plasma glucose
